Literature DB >> 30385657

Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

.   

Abstract

Entities:  

Year:  2018        PMID： 30385657     DOI： 10.1158/1078-0432.CCR-18-3193

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  1 in total

Review 1.  Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.

Authors:  Ambrogio Gagliano; Angela Prestifilippo; Ornella Cantale; Gianluca Ferini; Giacomo Fisichella; Paolo Fontana; Dorotea Sciacca; Dario Giuffrida
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.